NovoCure Ltd (NVCR)
NASDAQ:NVCR
NVCR Stock Chart & Stats
$10.97
-$0.69(-2.38%)
At close: 4:00 PM EST
$10.97
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$9.82 - $20.06
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.87M
Market Cap
$1.25B
Enterprise Value$1.43B
Total Cash (Recent Filing)$457.52M
Total Debt (Recent Filing)$290.00M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Apr 23, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding113,794,395
10 Day Avg. Volume1,204,158
30 Day Avg. Volume1,869,062
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.19
Enterprise Value/Gross Profit2.94
Enterprise Value/Ebitda-10.94
Forecast
1Y Price Target
$25.50Price Target Upside132.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$694.69M
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomePANOVA-4 Phase 2 trial meeting its disease control rate primary endpoint indicates the combination therapy produced clinical activity that could support broader development and commercial interest.
Commercial Launch StrategyExisting commercial and field teams can support the pancreatic launch without hiring extra sales staff, leveraging physician familiarity with tumor‑treating fields to limit launch costs and accelerate uptake.
Regulatory ApprovalFDA approval of Optune Pax for locally advanced pancreatic cancer, supported by randomized-trial survival benefits, creates a clear regulatory pathway to market access and clinician adoption.
Bears Say
Efficacy Uncertainty In Metastatic SettingObjective response rates and median overall survival in metastatic pancreatic cancer did not show a clear advantage versus historical controls, raising doubt about the regimen achieving a definitive benefit in a larger confirmatory trial.
Medicare Billing SuspensionMedicare billing privileges were revoked due to an administrative revalidation error, preventing billing to Medicare and Medicare Advantage and constraining near-term cash flow until privileges are reinstated.
Reimbursement And Commercial HeadwindsRequirement to secure US reimbursement codes before material revenues are realized, together with scaled-back commercial efforts for the non-small cell lung cancer program, may delay meaningful revenue and weaken near-term sales momentum.
NovoCure News
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $9.82 and its highest was $20.06 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.25B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Apr 23, 2026 which is in 24 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Feb 26, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.411 by $0.191.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.51.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 113,794,395 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.411. Following the earnings report the stock price went down -8.272%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.50 (132.45% Upside)
$25.50 (132.45% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 55.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $595.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.17%
12-Months-Change
Fundamentals
Return on Equity
-39.11%
Trailing 12-Months
Asset Growth
-35.18%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NVCR Company Deck
NVCR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong commercial and clinical progress (record revenue, meaningful active patient growth, FDA approval of Optune Pax, upcoming trial readouts, improved non‑GBM revenue trajectory, solid cash position and convertible note repayment) alongside near‑term profitability and operational challenges (net losses and negative adjusted EBITDA, gross margin compression, increased R&D spend, slower Optune Lua launch, reimbursement timing for Optune Pax, and a resolved Medicare administrative issue). Management provided formal 2026 guidance (revenue growth of 3%–8% and adjusted EBITDA of negative $20 million to breakeven), signifying a clear path toward stabilizing growth and driving to profitability while acknowledging near‑term execution and reimbursement risks.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$25.50
▲(132.45% Upside)
Technical Analysis
Ownership Overview
2.73% Insiders
21.71% Mutual Funds
16.42% Other Institutional Investors
43.39% Public Companies and
Individual Investors